Background: The initiation and cessation of opioid agonist treatment (OAT) have both been associated with elevated risk of fatal overdose. We examined risk of non-fatal overdose during OAT initiation and cessation and specifically between methadone versus buprenorphine recipients.
Methods: We utilised primary care electronic health records from the Clinical Practice Research Datalink to delineate a study cohort of adults aged 18-64 who were prescribed OAT between Jan 1, 1998 and Dec 31, 2017. These records were linked to hospitalisation, mortality records and patient neighbourhood and practice-level Index of Multiple Deprivation quintiles. With inverse probability treatment weights applied and negative binomial regression models we estimated incidence rate ratios for hospital admissions among patients who experienced multiple overdoses.
Findings: A total of 20898 patients were prescribed methadone or buprenorphine over 83856 person-years of follow-up. Compared with periods in treatment, patients not in treatment were 51% more likely to experience a non-fatal overdose that required hospitalisation (weighted rate ratio, wRR 1·51; 95% CI 1·42, 1·60), especially during the four weeks of OAT initiation (5·59; 5·31, 5·89) and following cessation (13·39; 12·78, 14·03). The wRR of overdose during (0·37; 0·34, 0·39) and after treatment (0·36; 0·34, 0·38) favoured buprenorphine compared to methadone.
Interpretation: OAT is associated with decreased non-fatal overdose risk. Buprenorphine may act more protectively than methadone, especially during the first four weeks of treatment.
Funding: National Institute for Health and Care Research (NIHR) Greater Manchester Patient Safety Translational Research Centre (PSTRC-2016-003).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399254 | PMC |
| http://dx.doi.org/10.1016/j.lanepe.2022.100489 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Insomnia Symptoms are Associated with Return to use and Non-fatal Overdose following Opioid Use Disorder Treatment.
Sleep
December 2024
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Study Objectives: Opioid use disorder (OUD) is a chronic, relapse-prone condition, often accompanied by sleep disturbances such as insomnia. While sleep disturbances have been implicated in negative treatment outcomes, no large-scale studies have examined the relationship between insomnia disorder and outcomes for persons completing an acute OUD treatment episode. This study assessed the association between insomnia symptoms at treatment intake, during treatment, and following acute treatment with post-treatment episode return to use, and non-fatal overdose outcomes.
View Article and Find Full Text PDFExemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098 an open-label randomized comparative effectiveness trial of extended-release buprenorphine versus treatment as usual on post-hospital treatment engagement for hospitalized patients with opioid use disorder.
Addict Sci Clin Pract
December 2024
Department of Medicine, Addiction Medicine Section, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239-3098, USA.
Article Synopsis
- The study is focused on the increasing issue of hospitalizations related to opioid use disorder (OUD), comparing standard addiction consultation services to a specific treatment involving a long-lasting buprenorphine injection to improve post-hospital care engagement.
- Patients in six U.S. hospitals who were not on medication for OUD before admission will be randomly assigned either to continue usual care or receive a single dose of a 28-day extended-release buprenorphine upon discharge.
- Outcomes will be assessed at multiple follow-up points, with the primary goal of seeing if the XR-BUP group shows higher engagement in ongoing treatment 34 days after leaving the hospital, while also monitoring for safety and various secondary effects.
Recovery Capital and Subsequent Overdose Risk and Addiction Treatment Engagement Among Emergency Department Patients at High Risk of Opioid Overdose.
Subst Use Misuse
December 2024
Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island.
Background: Emergency department (ED) visits are an opportunity to provide prevention services to people at high risk of overdose. Considering patients' resources to initiate and sustain recovery ("recovery capital") may be useful for tailoring ED services, although its relevance in this population is unknown.
Methods: This secondary analysis used data from ED patients at high risk of opioid overdose enrolled in a randomized controlled trial in Rhode Island (2018-2021).
Opioid substitution treatment, relapse and addiction-related outcomes in prison setting and after release: A longitudinal study.
Nordisk Alkohol Nark
December 2024
Department of Addiction Research, the University of Regensburg, Regensburg, Germany.
Opioid addiction is a common problem among prisoners. The aim of this study was to examine differences between people who are incarcerated receiving opioid substitution treatment (OST) and those not receiving OST on addiction-related outcome variables during incarceration and after release from prison. Variables covered illicit use of opioids, non-prescribed substitution medication and other substances, opioid withdrawal symptoms, opioid craving, non-fatal overdoses and post-release substitution treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!